About
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.
Current Value
$7.001 Year Return
Current Value
$7.001 Year Return
Key Details
Market Cap
$695.73M
P/E Ratio
-13.81
1Y Stock Return
-56.60%
1Y Revenue Growth
504.79%
Dividend Yield
0.00%
Price to Book
9.4
Strategies that include AVDL
Double maintains 3 strategies that include AVDL - Avadel Pharmaceuticals Plc
Health Care Sector
Medium risk
$14.0K
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
346
Stock's related to AVDL
The stocks that are correlated to AVDL - Avadel Pharmaceuticals Plc are IGMS, ROOT, NNOX, LMND, BTU
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| 34.75% | $69.34M | -86.95% | 0.00% | |
R ROOTRoot, Inc. | 32.62% | $1.83B | +69.79% | 0.00% |
N NNOXNano-X Imaging Ltd. | 32.54% | $273.20M | -57.04% | 0.00% |
L LMNDLemonade, Inc. | 30.69% | $2.18B | +85.29% | 0.00% |
| 30.19% | $1.45B | -48.78% | 2.62% | |
| 30.05% | $1.91B | +28.72% | 0.00% | |
| 29.98% | $735.55M | -21.79% | 5.46% | |
| 29.87% | $1.07B | -44.92% | 0.00% | |
| 29.82% | $1.12B | -41.04% | 0.00% | |
| 29.71% | $210.72M | -67.99% | 0.00% | |
| 29.58% | $6.11B | +9.06% | 0.00% | |
Q QTRXQuanterix Corp. | 29.48% | $240.80M | -71.25% | 0.00% |
E ETREntergy Corp. | 29.43% | $36.64B | +63.08% | 4.83% |
| 29.06% | $1.29B | -23.75% | 0.00% | |
V VNTVontier Corp. | 28.53% | $4.52B | -28.96% | 0.35% |
| 28.39% | $4.16M | +11.80% | 0.00% | |
M MATXMatson, Inc. | 28.24% | $3.78B | +4.63% | 1.20% |
O OSPNOneSpan, Inc. | 28.21% | $557.75M | +28.50% | 0.87% |
R RELYRemitly Global, Inc. | 27.79% | $4.04B | -1.42% | 0.00% |
N NXTNextracker, Inc. | 27.74% | $5.81B | -19.97% | 0.00% |
ETF's related to AVDL
The ETFs that are correlated to AVDL - Avadel Pharmaceuticals Plc are XBI, IWC, CPSJ, CPRJ, IWO
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
X XBISPDR Biotech ETF | 27.16% | $5.06B | 0.35% |
| 26.80% | $809.63M | 0.6% | |
| 26.01% | $33.02M | 0.69% | |
| 25.90% | $48.65M | 0.69% | |
| 24.96% | $10.93B | 0.24% | |
| 24.95% | $158.44M | 0.35% | |
| 24.73% | $110.09M | 0.6% | |
| 23.97% | $63.84B | 0.19% | |
| 23.89% | $11.24B | 0.07% | |
| 23.85% | $521.56M | 0.2% | |
| 23.74% | $120.94M | 0.93% | |
| 23.67% | $5.70B | 0.45% | |
| 23.49% | $169.45M | 0.79% | |
| 23.46% | $649.33M | 0.65% | |
| 23.08% | $36.81M | 0.84% | |
| 23.02% | $715.67M | 0.38% | |
| 22.88% | $666.40M | 0.06% | |
| 22.75% | $2.31B | 0.3% | |
| 22.73% | $16.19B | 0.04% | |
| 22.69% | $229.13M | 0.58% | |
News
Yahoo
DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference on Tuesday, April 8 at 1:30 p.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days foll
Yahoo
DUBLIN, March 25, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of six manuscripts covering clinical management, shared decision-making and goal setting for people with narcolepsy and their clinicians in a CNS Drugs supplement titled “A New Dawn in the Management of Narcolepsy”. “I am delighted to serve as guest editor for the recently published CNS Drugs supple
SeekingAlpha
Discover three undervalued biotech stocks with strong assets, solid cash reserves, and major catalysts ahead. Click for the picks and why I like them.
Yahoo
DUBLIN, Ireland, March 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Leerink Global Biopharma Conference: Fireside chat on Wednesday, March 12 at 9:20 a.m. ET.UBS Virtual CNS Day: Fireside chat on Monday, March 17 at 8:30 a.m. ET. A live webcast of these events, as well as archived r
Yahoo
Avadel Pharmaceuticals ( NASDAQ:AVDL ) Full Year 2024 Results Key Financial Results Revenue: US$169.1m (up by US$141.2m...
Yahoo
Avadel Pharmaceuticals PLC (AVDL) reports a significant increase in revenue and achieves cash flow positivity, while projecting robust growth for 2025 despite ongoing challenges.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds